Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting

Current Oncology

Volumn 19, Issue 6, 2012, Pages

  Bouganim, N ^a   Dranitsaris, G ^a   Hopkins, S ^a   Vandermeer, L ^a   Godbout, L ^a   Dent, S ^a   Wheatley Price, P ^a   Milano, C ^a   Clemons, M ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Aprepitant; Chemotherapy; Nausea and vomiting

Indexed keywords

ALCOHOL; ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; DEXAMETHASONE; GRANISETRON; ONDANSETRON; PLATINUM COMPLEX; PROCHLORPERAZINE;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORNING SICKNESS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; SYMPTOM; TELEPHONE; VALIDATION STUDY;

EID: 84870742915     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1074     Document Type: Article

References (10)

1. Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer 1994;2:286-92.
2. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for anti-emetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-6.
3. Herrstedt J, Roila F on behalf of the esmo Guidelines Working Group. Chemotherapy-induced nausea and vomiting: esmo clinical recommendations for prophylaxis. Ann Oncol 2008;19(suppl 2):ii110-12.
4. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for anti-emetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47.
5. Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 1996;53(suppl 1):26-31.
6. Roscoe JA, Morrow GR, Colagiuri B, et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 2010;18:869-76.
7. Booth CM, Clemons M, Dranitsaris G, et al. Chemotherapyinduced nausea and vomiting in breast cancer patients: a prospective observational study. J Supp Oncol 2007;5:374-80.
8. Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospitalbased study. Support Care Cancer 2012;20:107-17.
9. Dranitsaris G, Joy A, Young S, Clemons M, Callaghan W, Petrella T. Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool. I. Acute nausea and vomiting. J Support Oncol 2009;7:W1-8.
10. Petrella T, Clemons M, Joy A, Young S, Callaghan W, Dranitsaris G. Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool. II. Delayed nausea and vomiting. J Support Oncol 2009;7:W9-16.